Systemic (Oral) Dexamethasone and Oral Candidiasis (Thrush)
Daily oral dexamethasone can contribute to oral candidiasis (thrush). This adverse effect is mediated by corticosteroid–associated impairment of host immune responses and disruption of the normal oral fungal balance. [1]
Mechanism of Predisposition
Corticosteroid exposure increases the risk of oropharyngeal candidiasis by reducing local immune control of Candida overgrowth. [1]
Evidence Linking Corticosteroids to Oropharyngeal Disease
Oropharyngeal and esophageal candidiasis are associated with steroid use, including systemic steroid exposure. [1]
Clinical Evidence for Systemic Glucocorticoid Exposure
A study of patients undergoing systemic glucocorticoid therapy found increased oral Candida colonization patterns consistent with heightened susceptibility to oral candidiasis. [2]
Risk Factors That Commonly Co-Occur With Steroid-Associated Thrush
Risk is increased by immunocompromising conditions and by antimicrobial exposure, which commonly co-occur with steroid therapy. [1]
Practical Risk Reduction Measures
Oral hygiene measures are recommended as part of preventing candidiasis. [3]
When to Seek Evaluation
Clinical evaluation is warranted when thrush does not improve with appropriate antifungal therapy, recurs, or occurs with severe symptoms suggestive of more extensive infection (for example, esophageal symptoms). [1]
Treatment Implications for Suspected Thrush on Dexamethasone
For symptomatic oral candidiasis, management typically includes antifungal therapy; corticosteroid modification or temporary discontinuation is guided by the underlying condition requiring dexamethasone and infection severity. [1]